AFT's disclosure lacks candour despite chair's pedigree

AFT's disclosure lacks candour despite chair's pedigree
AFT Pharmaceuticals chair David Flacks has a strong background in regulation and governance.
Jenny Ruth
It's hard to fathom that AFT Pharmaceuticals' management and board only realised late on the company's balance date that it was going to miss its earnings guidance by as much as 50%.Founder and managing director Hartley Atkinson assured BusinessDesk that is what happened.AFT has two distinct revenue streams. Licensing agreements and milestone payments are by nature lumpy, and it's easy to understand that Atkinson and his team may have been expecting deals to be signed by March 31, only to see the timing slip a couple of weeks or...

More Markets

Robust update from Tauranga Port perks up NZX
Markets Market close

Robust update from Tauranga Port perks up NZX

Numbers hide 'a lot of paddling' going on under the surface. 

Graham Skellern 25 Oct 2024
Jarden upgrades Michael Hill ahead of Christmas
Finance

Jarden upgrades Michael Hill ahead of Christmas

Since a Wednesday trading update, company's shares have risen 9%.

Gregor Thompson 25 Oct 2024
NZ Windfarms buys NZ's oldest windfarm
Infrastructure

NZ Windfarms buys NZ's oldest windfarm

Bottom end of ebitdaf guidance is $1.5m higher than previous estimate.

John Anthony 25 Oct 2024
Winton chair defends Sunfield development
Property

Winton chair defends Sunfield development

Winton wants to develop the Sunfield masterplanned community at Takanini.

Gregor Thompson 25 Oct 2024